Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.6%.
The iShares Biotechnology ETF (IBB) added 1.1%.
In corporate news, Novo Nordisk (NVO) said it launched a direct-to-patient delivery option that offers patients all dose strengths of Wegovy at a reduced cost. Novo shares gained 3.4%.
Amgen (AMGN) has started two phase 3 trials for its obesity drug MariTide, the company's Head of Research and Development, Jay Bradner, said Wednesday at an investor conference. Amgen shares rose 1.4%.
Merck (MRK) is facing a patent dispute that threatens its plans to sell a new version of Keytruda, its top-selling cancer drug, the Wall Street Journal reported. Merck shares were fractionally higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.